You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNizatidine
Accession NumberDB00585  (APRD00706)
TypeSmall Molecule
GroupsApproved
DescriptionA histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. [PubChem]
Structure
Thumb
Synonyms
Nizatidina
Nizatidine
Nizatidinum
External Identifiers
  • LY-139037
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Axidcapsule150 mgoralPendopharm Division Of De Pharmascience Inc1988-12-31Not applicableCanada
Axidcapsule300 mgoralPendopharm Division Of De Pharmascience Inc1988-12-31Not applicableCanada
Dom-nizatidine 150mg Capsulescapsule150 mgoralDominion Pharmacal2001-10-31Not applicableCanada
Gen-nizatidinecapsule150 mgoralGenpharm Ulc2002-07-122010-08-04Canada
Gen-nizatidinecapsule300 mgoralGenpharm Ulc2002-07-122010-08-04Canada
Nizatidine-150capsule150 mgoralPro Doc Limitee2001-02-122010-07-13Canada
Nizatidine-300capsule300 mgoralPro Doc Limitee2001-02-122010-07-13Canada
Novo-nizatidinecapsule150 mgoralNovopharm Limited1999-07-23Not applicableCanada
Novo-nizatidinecapsule300 mgoralNovopharm Limited1999-07-23Not applicableCanada
Nu-nizatidinecapsule150 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-nizatidinecapsule300 mgoralNu Pharm IncNot applicableNot applicableCanada
PHL-nizatidinecapsule300 mgoralPharmel Inc1999-03-01Not applicableCanada
PHL-nizatidinecapsule150 mgoralPharmel Inc1999-03-01Not applicableCanada
PMS-nizatidinecapsule300 mgoralPharmascience Inc1998-04-28Not applicableCanada
PMS-nizatidine 150mg Capsulescapsule150 mgoralPharmascience Inc1998-04-28Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-nizatidinecapsule300 mgoralApotex Inc1998-12-31Not applicableCanada
Apo-nizatidinecapsule150 mgoralApotex Inc1998-12-31Not applicableCanada
Nizatidinecapsule300 mg/1oralGlenmark Generics Inc.,USA2011-07-15Not applicableUs
Nizatidinecapsule300 mg/1oralRebel Distributors Corp2002-07-09Not applicableUs
Nizatidinecapsule150 mg/1oralProficient Rx LP2011-07-15Not applicableUs
Nizatidinecapsule150 mg/1oralEon Labs, Inc.2002-07-05Not applicableUs
Nizatidinecapsule150 mg/1oralH.J. Harkins Company, Inc.2002-07-09Not applicableUs
Nizatidinecapsule150 mg/1oralCarilion Materials Management2002-07-09Not applicableUs
Nizatidinecapsule150 mg/1oralWatson Laboratories, Inc.2002-07-09Not applicableUs
Nizatidinecapsule150 mg/1oralPreferred Pharmaceuticals Inc.2015-08-28Not applicableUs
Nizatidinecapsule150 mg/1oralRebel Distributors Corp2002-07-05Not applicableUs
Nizatidinecapsule300 mg/1oralEon Labs, Inc.2002-07-05Not applicableUs
Nizatidinecapsule300 mg/1oralbryant ranch prepack2005-09-15Not applicableUs
Nizatidinecapsule150 mg/1oralDr Reddy's Laboratories Limited2005-09-15Not applicableUs
Nizatidinecapsule300 mg/1oralDispensing Solutions Inc.2009-01-22Not applicableUs
Nizatidinecapsule300 mg/1oralWatson Laboratories, Inc.2002-07-09Not applicableUs
Nizatidinecapsule150 mg/1oralRebel Distributors Corp2002-07-09Not applicableUs
Nizatidinecapsule150 mg/1oralPreferred Pharmaceuticals, Inc2012-03-29Not applicableUs
Nizatidinecapsule150 mg/1oralMylan Pharmaceuticals Inc.2011-05-04Not applicableUs
Nizatidinecapsule150 mg/1oralbryant ranch prepack2005-09-15Not applicableUs
Nizatidinecapsule300 mg/1oralDr Reddy's Laboratories Limited2005-09-15Not applicableUs
Nizatidinecapsule150 mg/1oralGlenmark Generics Inc.,USA2011-07-15Not applicableUs
Nizatidinecapsule150 mg/1oralnizatidine2010-01-14Not applicableUs
Nizatidinecapsule150 mg/1oralMedsource Pharmaceuticals2011-07-15Not applicableUs
Nizatidinesolution15 mg/mLoralAmneal Pharmaceuticals2009-12-14Not applicableUs
Nizatidinecapsule300 mg/1oralMylan Pharmaceuticals Inc.2011-05-06Not applicableUs
Nizatidinecapsule150 mg/1oralLake Erie Medical DBA Quality Care Products LLC2002-07-09Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Axid Artablet, film coated75 mg/1oralWyeth Consumer Healthcare1996-05-09Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
AcinonNot Available
TazacEli Lilly
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIP41PML4GHR
CAS number76963-41-2
WeightAverage: 331.45
Monoisotopic: 331.113667284
Chemical FormulaC12H21N5O2S2
InChI KeySGXXNSQHWDMGGP-UHFFFAOYSA-N
InChI
InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3
IUPAC Name
dimethyl[(4-{[(2-{[1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}-1,3-thiazol-2-yl)methyl]amine
SMILES
CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 2,4-disubstituted thiazoles. These are compounds containing a thiazole ring substituted at the positions 2 and 3.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassThiazoles
Direct Parent2,4-disubstituted thiazoles
Alternative Parents
Substituents
  • 2,4-disubstituted 1,3-thiazole
  • Aralkylamine
  • Heteroaromatic compound
  • C-nitro compound
  • Tertiary amine
  • Tertiary aliphatic amine
  • Organic nitro compound
  • Organic oxoazanium
  • Thioether
  • Sulfenyl compound
  • Allyl-type 1,3-dipolar organic compound
  • Propargyl-type 1,3-dipolar organic compound
  • Organic 1,3-dipolar compound
  • Dialkylthioether
  • Azacycle
  • Organic oxide
  • Amine
  • Organic zwitterion
  • Organic oxygen compound
  • Organic nitrogen compound
  • Organonitrogen compound
  • Organosulfur compound
  • Organic salt
  • Hydrocarbon derivative
  • Organopnictogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.
PharmacodynamicsNizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells. By inhibiting the action of histamine on stomach cells, nizatidine reduces stomach acid production. Nizatidine had no demonstrable antiandrogenic action. Full-dose therapy for the problems treated by nizatidine lasts no longer than 8 weeks. It has been demonstrated that treatment with a reduced dose of nizatidine is effective as maintenance therapy following healing of active duodenal ulcers.
Mechanism of actionNizatidine competes with histamine for binding at the H2-receptors on the gastric basolateral membrane of parietal cells. Competitive inhibition results in reduction of basal and nocturnal gastric acid secretions. The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin.
Related Articles
AbsorptionRapid (bioavailability of nizatidine exceeds 70%)
Volume of distribution
  • 0.8 to 1.5 L/kg
Protein binding35%
Metabolism

Hepatic. Less than 7% of an oral dose is metabolized as N2-monodes-methylnizatidine, an H2-receptor antagonist, which is the principal metabolite excreted in the urine. Other likely metabolites are the N2-oxide (less than 5% of the dose) and the S-oxide (less than 6% of the dose).

SubstrateEnzymesProduct
Nizatidine
Not Available
N2-monodes-methylnizatidineDetails
Route of eliminationNot Available
Half life1-2 hours
Clearance
  • 40-60 L/h
  • 7 – 14 L/h [functionally anephric patients]
ToxicityOral, rat LD50: 301 mg/kg. Symptoms of overdose include cholinergic-type effects including lacrimation, salivation, emesis, miosis, and diarrhea.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Nizatidine Action PathwayDrug actionSMP00233
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9572
Blood Brain Barrier+0.5
Caco-2 permeable-0.589
P-glycoprotein substrateSubstrate0.8357
P-glycoprotein inhibitor INon-inhibitor0.8947
P-glycoprotein inhibitor IINon-inhibitor0.8861
Renal organic cation transporterNon-inhibitor0.7832
CYP450 2C9 substrateNon-substrate0.8108
CYP450 2D6 substrateNon-substrate0.6721
CYP450 3A4 substrateNon-substrate0.5916
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8508
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7826
Ames testNon AMES toxic0.6129
CarcinogenicityNon-carcinogens0.9182
BiodegradationNot ready biodegradable0.9295
Rat acute toxicity2.4350 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6244
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Smithkline beecham corp dba glaxosmithkline
  • Apotex inc
  • Dr reddys laboratories ltd
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Braintree laboratories inc
  • Amneal pharmaceuticals
  • Wyeth consumer healthcare
Packagers
Dosage forms
FormRouteStrength
Capsuleoral300 mg
Tablet, film coatedoral75 mg/1
Capsuleoral150 mg
Capsuleoral150 mg/1
Capsuleoral300 mg/1
Solutionoral15 mg/mL
Prices
Unit descriptionCostUnit
Axid 300 mg pulvule6.0USD each
Nizatidine 300 mg capsule4.97USD capsule
Axid 300 mg Capsule3.98USD capsule
Axid 150 mg pulvule3.62USD each
Nizatidine 150 mg capsule2.48USD capsule
Axid 150 mg Capsule2.06USD capsule
Apo-Nizatidine 300 mg Capsule0.96USD capsule
Novo-Nizatidine 300 mg Capsule0.96USD capsule
Pms-Nizatidine 300 mg Capsule0.96USD capsule
Axid 15 mg/ml Solution0.84USD ml
Nizatidine 15 mg/ml Solution0.76USD ml
Apo-Nizatidine 150 mg Capsule0.53USD capsule
Gen-Nizatidine 150 mg Capsule0.53USD capsule
Novo-Nizatidine 150 mg Capsule0.53USD capsule
Pms-Nizatidine 150 mg Capsule0.53USD capsule
Axid ar 75 mg tablet0.3USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6930119 No2002-07-172022-07-17Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point130-132 °CPhysProp
water solubility10-33mg/mLNot Available
logP1.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0386 mg/mLALOGPS
logP0.7ALOGPS
logP0.77ChemAxon
logS-3.9ALOGPS
pKa (Strongest Basic)6.54ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area83.33 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity95.84 m3·mol-1ChemAxon
Polarizability35.54 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Charles W. Ryan, Bruce A. Slomski, “Synthesis of nizatidine intermediate.” U.S. Patent US4777260, issued June, 1983.

US4777260
General ReferencesNot Available
External Links
ATC CodesA02BA04
AHFS Codes
  • 56:28.12
PDB EntriesNot Available
FDA labelDownload (380 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Nizatidine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Nizatidine.
AcetaminophenThe serum concentration of Nizatidine can be increased when it is combined with Acetaminophen.
AfatinibThe serum concentration of Nizatidine can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Nizatidine can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Nizatidine can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Nizatidine can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Nizatidine can be increased when it is combined with Alfentanil.
AmantadineThe serum concentration of Nizatidine can be increased when it is combined with Amantadine.
Aminohippuric acidThe serum concentration of Nizatidine can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Nizatidine can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Nizatidine can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Nizatidine can be increased when it is combined with Amlodipine.
AmphetamineAmphetamine may decrease the sedative activities of Nizatidine.
AmprenavirThe serum concentration of Nizatidine can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Nizatidine can be increased when it is combined with Amsacrine.
AstemizoleThe serum concentration of Nizatidine can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Nizatidine.
AtazanavirThe serum concentration of Nizatidine can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Nizatidine can be increased when it is combined with Atenolol.
AtorvastatinThe serum concentration of Nizatidine can be increased when it is combined with Atorvastatin.
AzelastineThe serum concentration of Nizatidine can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Nizatidine can be increased when it is combined with Azithromycin.
BenzocaineThe serum concentration of Nizatidine can be increased when it is combined with Benzocaine.
BenzphetamineBenzphetamine may decrease the sedative activities of Nizatidine.
Benzylpenicilloyl PolylysineNizatidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BepridilThe serum concentration of Nizatidine can be increased when it is combined with Bepridil.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Nizatidine.
BiperidenThe serum concentration of Nizatidine can be increased when it is combined with Biperiden.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Nizatidine.
BosutinibThe serum concentration of Nizatidine can be increased when it is combined with Bosutinib.
BromocriptineThe serum concentration of Nizatidine can be increased when it is combined with Bromocriptine.
BuprenorphineThe serum concentration of Nizatidine can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Nizatidine can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Nizatidine can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Nizatidine can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Nizatidine can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Nizatidine can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Nizatidine can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Nizatidine can be decreased when it is combined with Carbamazepine.
CarvedilolThe serum concentration of Nizatidine can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Nizatidine can be increased when it is combined with Caspofungin.
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Nizatidine.
CefpodoximeNizatidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.
CefuroximeNizatidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.
ChloroquineThe serum concentration of Nizatidine can be increased when it is combined with Chloroquine.
ChlorphentermineChlorphentermine may decrease the sedative activities of Nizatidine.
ChlorpromazineThe serum concentration of Nizatidine can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Nizatidine can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Nizatidine can be increased when it is combined with Chlorprothixene.
CholesterolThe serum concentration of Nizatidine can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Nizatidine can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Nizatidine can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Nizatidine can be decreased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Nizatidine can be increased when it is combined with Ciprofloxacin.
CitalopramThe serum concentration of Nizatidine can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Nizatidine can be increased when it is combined with Clarithromycin.
ClofazimineThe serum concentration of Nizatidine can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Nizatidine can be increased when it is combined with Clomipramine.
ClotrimazoleThe serum concentration of Nizatidine can be decreased when it is combined with Clotrimazole.
CobicistatThe serum concentration of Nizatidine can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Nizatidine can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Nizatidine can be increased when it is combined with Colforsin.
CrizotinibThe serum concentration of Nizatidine can be increased when it is combined with Crizotinib.
CyclophosphamideThe serum concentration of Nizatidine can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Nizatidine can be decreased when it is combined with Cyclosporine.
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Nizatidine.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Nizatidine.
DaclatasvirThe serum concentration of Nizatidine can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Nizatidine can be increased when it is combined with Dactinomycin.
DasatinibNizatidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
DasatinibThe serum concentration of Nizatidine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Nizatidine can be decreased when it is combined with Daunorubicin.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Nizatidine.
DesipramineThe serum concentration of Nizatidine can be increased when it is combined with Desipramine.
DesloratadineThe serum concentration of Nizatidine can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Nizatidine can be decreased when it is combined with Dexamethasone.
DexmethylphenidateNizatidine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Nizatidine.
DextromethorphanThe serum concentration of Nizatidine can be increased when it is combined with Dextromethorphan.
DiclofenacThe serum concentration of Nizatidine can be increased when it is combined with Diclofenac.
DigoxinThe serum concentration of Nizatidine can be decreased when it is combined with Digoxin.
DihydroergotamineThe serum concentration of Nizatidine can be increased when it is combined with Dihydroergotamine.
DiltiazemThe serum concentration of Nizatidine can be increased when it is combined with Diltiazem.
DipyridamoleThe serum concentration of Nizatidine can be increased when it is combined with Dipyridamole.
DoxazosinThe serum concentration of Nizatidine can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Nizatidine can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Nizatidine can be decreased when it is combined with Doxorubicin.
DronabinolThe serum concentration of Nizatidine can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Nizatidine can be increased when it is combined with Dronedarone.
ElbasvirThe serum concentration of Nizatidine can be increased when it is combined with Elbasvir.
EnalaprilThe serum concentration of Nizatidine can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Nizatidine can be increased when it is combined with Enzalutamide.
ErgonovineThe serum concentration of Nizatidine can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Nizatidine can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Nizatidine.
ErythromycinThe serum concentration of Nizatidine can be decreased when it is combined with Erythromycin.
EstramustineThe serum concentration of Nizatidine can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Nizatidine can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Nizatidine can be decreased when it is combined with Estrone.
EtoposideThe serum concentration of Nizatidine can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Nizatidine can be increased when it is combined with Etravirine.
FelodipineThe serum concentration of Nizatidine can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Nizatidine can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Nizatidine can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Nizatidine can be increased when it is combined with Fidaxomicin.
FluconazoleThe serum concentration of Nizatidine can be increased when it is combined with Fluconazole.
FluoxetineThe serum concentration of Nizatidine can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Nizatidine can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Nizatidine can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Nizatidine can be increased when it is combined with Flurazepam.
FluvoxamineThe serum concentration of Nizatidine can be increased when it is combined with Fluvoxamine.
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Nizatidine.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Nizatidine.
GefitinibThe serum concentration of Nizatidine can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Nizatidine can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Nizatidine can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Nizatidine can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Nizatidine can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Nizatidine can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Nizatidine can be increased when it is combined with Haloperidol.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Nizatidine.
HydrocortisoneThe serum concentration of Nizatidine can be increased when it is combined with Hydrocortisone.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Nizatidine.
IdelalisibThe serum concentration of Nizatidine can be increased when it is combined with Idelalisib.
ImatinibThe serum concentration of Nizatidine can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Nizatidine can be increased when it is combined with Imipramine.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Nizatidine.
IndomethacinThe serum concentration of Nizatidine can be increased when it is combined with Indomethacin.
IsavuconazoniumThe serum concentration of Nizatidine can be increased when it is combined with Isavuconazonium.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Nizatidine.
ItraconazoleThe serum concentration of Nizatidine can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Nizatidine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Nizatidine can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Nizatidine can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Nizatidine.
KetoconazoleThe serum concentration of Nizatidine can be increased when it is combined with Ketoconazole.
LansoprazoleThe serum concentration of Nizatidine can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Nizatidine can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Nizatidine.
LevofloxacinThe serum concentration of Nizatidine can be increased when it is combined with Levofloxacin.
LevothyroxineThe serum concentration of Nizatidine can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Nizatidine can be increased when it is combined with Lidocaine.
LiothyronineThe serum concentration of Nizatidine can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Nizatidine can be decreased when it is combined with Liotrix.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Nizatidine.
LisinoprilThe serum concentration of Nizatidine can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Nizatidine can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Nizatidine can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Nizatidine can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Nizatidine can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Nizatidine can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Nizatidine can be increased when it is combined with Lovastatin.
LumacaftorThe serum concentration of Nizatidine can be decreased when it is combined with Lumacaftor.
MaprotilineThe serum concentration of Nizatidine can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Nizatidine can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Nizatidine can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Nizatidine can be increased when it is combined with Megestrol acetate.
MephentermineMephentermine may decrease the sedative activities of Nizatidine.
MeprobamateThe serum concentration of Nizatidine can be increased when it is combined with Meprobamate.
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Nizatidine.
MethadoneThe serum concentration of Nizatidine can be increased when it is combined with Methadone.
MethamphetamineMethamphetamine may decrease the sedative activities of Nizatidine.
MethylphenidateNizatidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
MetoprololThe serum concentration of Nizatidine can be increased when it is combined with Metoprolol.
MibefradilThe serum concentration of Nizatidine can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Nizatidine can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Nizatidine can be decreased when it is combined with Midazolam.
MifepristoneThe serum concentration of Nizatidine can be decreased when it is combined with Mifepristone.
MitomycinThe serum concentration of Nizatidine can be increased when it is combined with Mitomycin.
MitoxantroneThe serum concentration of Nizatidine can be decreased when it is combined with Mitoxantrone.
MorphineThe serum concentration of Nizatidine can be increased when it is combined with Morphine.
NaltrexoneThe serum concentration of Nizatidine can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Nizatidine can be increased when it is combined with Naringenin.
NefazodoneThe serum concentration of Nizatidine can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Nizatidine.
NeostigmineThe serum concentration of Nizatidine can be increased when it is combined with Neostigmine.
NicardipineThe serum concentration of Nizatidine can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Nizatidine can be decreased when it is combined with Nifedipine.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Nizatidine.
NilotinibThe serum concentration of Nizatidine can be increased when it is combined with Nilotinib.
NisoldipineThe serum concentration of Nizatidine can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Nizatidine can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Nizatidine can be increased when it is combined with Nitrendipine.
NorethisteroneThe serum concentration of Nizatidine can be decreased when it is combined with Norethisterone.
OmeprazoleThe serum concentration of Nizatidine can be increased when it is combined with Omeprazole.
P-NitrophenolThe serum concentration of Nizatidine can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Nizatidine can be increased when it is combined with Paclitaxel.
Palmitic AcidThe serum concentration of Nizatidine can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Nizatidine can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Nizatidine can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Nizatidine.
PerindoprilThe serum concentration of Nizatidine can be increased when it is combined with Perindopril.
PhenobarbitalThe serum concentration of Nizatidine can be decreased when it is combined with Phenobarbital.
PhenterminePhentermine may decrease the sedative activities of Nizatidine.
PimozideThe serum concentration of Nizatidine can be increased when it is combined with Pimozide.
Platelet Activating FactorThe serum concentration of Nizatidine can be decreased when it is combined with Platelet Activating Factor.
PonatinibThe serum concentration of Nizatidine can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Nizatidine.
PosaconazoleThe serum concentration of Nizatidine can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Nizatidine can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Nizatidine can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Nizatidine can be increased when it is combined with Prednisone.
ProbenecidThe serum concentration of Nizatidine can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Nizatidine can be decreased when it is combined with Progesterone.
PromethazineThe serum concentration of Nizatidine can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Nizatidine can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Nizatidine can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Nizatidine can be increased when it is combined with Protriptyline.
QuercetinThe serum concentration of Nizatidine can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Nizatidine can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Nizatidine can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Nizatidine can be increased when it is combined with Quinine.
RanitidineThe serum concentration of Nizatidine can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Nizatidine can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Nizatidine can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Nizatidine can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Nizatidine can be decreased when it is combined with Reserpine.
RifampicinThe serum concentration of Nizatidine can be decreased when it is combined with Rifampicin.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Nizatidine.
RilpivirineThe serum concentration of Nizatidine can be increased when it is combined with Rilpivirine.
RisedronateThe serum concentration of Risedronate can be increased when it is combined with Nizatidine.
RitonavirThe serum concentration of Nizatidine can be decreased when it is combined with Ritonavir.
RolapitantThe serum concentration of Nizatidine can be increased when it is combined with Rolapitant.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Nizatidine.
SaquinavirThe serum concentration of Nizatidine can be decreased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Nizatidine can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Nizatidine can be increased when it is combined with Selegiline.
SertralineThe serum concentration of Nizatidine can be increased when it is combined with Sertraline.
SimeprevirThe serum concentration of Nizatidine can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Nizatidine can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Nizatidine can be decreased when it is combined with Sirolimus.
SorafenibThe serum concentration of Nizatidine can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Nizatidine can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Nizatidine can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Nizatidine can be increased when it is combined with Staurosporine.
StreptozocinThe serum concentration of Nizatidine can be decreased when it is combined with Streptozocin.
SulfinpyrazoneThe serum concentration of Nizatidine can be increased when it is combined with Sulfinpyrazone.
SumatriptanThe serum concentration of Nizatidine can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Nizatidine can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Nizatidine can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Nizatidine can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Nizatidine can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Nizatidine can be increased when it is combined with Taurocholic Acid.
TelmisartanThe serum concentration of Nizatidine can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Nizatidine can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Nizatidine can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Nizatidine can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Nizatidine can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Nizatidine can be increased when it is combined with Testosterone.
TicagrelorThe serum concentration of Nizatidine can be increased when it is combined with Ticagrelor.
TolvaptanThe serum concentration of Nizatidine can be increased when it is combined with Tolvaptan.
TrazodoneThe serum concentration of Nizatidine can be decreased when it is combined with Trazodone.
TrifluoperazineThe serum concentration of Nizatidine can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Nizatidine can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Nizatidine can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Nizatidine can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Nizatidine can be increased when it is combined with Troleandomycin.
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Nizatidine.
VenlafaxineThe serum concentration of Nizatidine can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Nizatidine can be decreased when it is combined with Verapamil.
VinblastineThe serum concentration of Nizatidine can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Nizatidine can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Nizatidine can be increased when it is combined with Vinorelbine.
ZimelidineThe serum concentration of Nizatidine can be increased when it is combined with Zimelidine.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Do not take Aluminum or magnesium antacids or supplements while on this medication.
  • May take Vitamin D.
  • No iron, zinc or fluoride within 2 hours of taking this medication.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) si...
Gene Name:
HRH2
Uniprot ID:
P25021
Molecular Weight:
40097.65 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Enriz RD, Jauregui EA: [Theoretical conformation study of tiotidine and nizatidine, two strong histamine H2-receptor antagonists]. Acta Cient Venez. 1991;42(2):70-6. [PubMed:1843561 ]
  3. Meredith CG, Speeg KV Jr, Schenker S: Nizatidine, a new histamine H2-receptor antagonist, and hepatic oxidative drug metabolism in the rat: a comparison with structurally related compounds. Toxicol Appl Pharmacol. 1985 Feb;77(2):315-24. [PubMed:2858133 ]
  4. Lin TM, Evans DC, Warrick MW, Pioch RP: Actions of nizatidine, a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs. J Pharmacol Exp Ther. 1986 Nov;239(2):406-10. [PubMed:2877081 ]
  5. Okabe S, Takeuchi K, Okada M, Kumadaki Y, Nakata M, Nakata H: [Effects of nizatidine, a new histamine H2-receptor antagonist, on gastric acid secretion and various gastric and duodenal lesions in rats: comparison with cimetidine]. Nihon Yakurigaku Zasshi. 1989 Mar;93(3):133-44. [PubMed:2567267 ]
  6. Kounenis G, Koutsoviti-Papadopoulou M, Elezoglou V: The excitatory effect of the new histamine H2-receptor antagonist nizatidine (LY 139037) on the guinea pig ileum. J Pharmacobiodyn. 1987 Nov;10(11):669-72. [PubMed:2895808 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Laine-Cessac P, Turcant A, Premel-Cabic A, Boyer J, Allain P: Inhibition of cholinesterases by histamine 2 receptor antagonist drugs. Res Commun Chem Pathol Pharmacol. 1993 Feb;79(2):185-93. [PubMed:8095733 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 30, 2016 02:26